In our study, MPT0G449 exhibited strong anticancer activity in leukemia (Table 1 and Fig. 6) and showed an extensive inhibitory effect on both phosphorylated and total AKT/mTOR, STAT3/5, and MEK/ERK protein expression (Fig. 5). Here, MAP2K7 is linked to leukemia.